NEWS

EDAP TMS

Since inception in 1979, EDAP TMS has been committed to introducing new and innovative technologies for minimally-invasive treatments of urological disorders.

These proprietary technologies such as HIFU (High Intensity Focused Ultrasound) or Electroconductive shock waves result from historical and efficient partnerships with INSERM (LabTau) and clinical institutions (HCL) which have yielded new minimally invasive procedures for the treatment of several pathologies such as localized prostate cancer or urinary tract stones. The strength of EDAP TMS' R&D is to master mechanical, acoustic, electronic and IT technologies to produce state-of-the-art and ergonomic medical devices.

Treatment of localized prostate cancer and HIFU Technology

EDAP’s Ablatherm®-HIFU is a robotic minimally invasive and effective treatment recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA.

Prostate cancer management is currently switching from current radical approach to a focal or partial approach of prostate cancer, aiming at controlling the cancer by limiting the treatment to tumor areas only. Due to its precision, low morbidity and repeatability, Ablatherm-HIFU is currently the best positioned technology to fit the new focal approach combining efficacy and preservation of patient quality of life.

EDAP, and its partners, were recently awarded a EUR 2.4 million grant by F.U.I. (Fond Unique Inter-ministériel) to further develop the HIFU focal approach of localized prostate cancer by incorporating improved imaging and diagnostic techniques (IDITOP Project - Imaging DIagnostic and Treatment Of Prostate cancer).

The Company is also working on various other applications where HIFU could provide an alternative to current invasive therapies.

Treatment of urinary stones

The Company also produces and markets devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. ESWL uses extracorporeal shockwaves, which can be focused at urinary stones within the human body to fragment the stones, thereby permitting their natural elimination and preventing the need for incisions, transfusions, general anaesthesia, and the resulting complications. In recent years, EDAP has renewed its product by launching two state-of-the-art lithotripters line (the Sonolith® i-sys and Sonolith® i-move) that feature its innovative stereovision and ultrasound localization systems.

News

2011/08/24 - EDAP Partnership Wins EUR 2.4 Million Grant for Development of Innovative Imaging Solution for Focal Treatment of Prostate Cancer

Read the press release

Documents

Brochure Ablatherm®-HIFU : télécharger

Brochure Sonolith® i-sys : télécharger

Brochure Sonolith® i-move : télécharger

For more information about EDAP TMS company

EDAP TMS S.A.

4, rue du Dauphiné - 69120 Vaulx-en-Velin • FRANCE

Blandine CONFORT, Investor Relations / Legal Affairs

E-mail : bconfort@edap-tms.com